Autopsy report · NCT04936113

Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 Study

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Failure of the Phase 2 study (protocol FB401-01) to meet its endpoint.”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 4 months before it stopped.
36 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: Forte Biosciences, Inc.
Sponsor type: Industry
Conditions: Atopic Dermatitis
Interventions: FB-401
Participants: 36
Sites: 8
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.